GLADEL–PANLAR 系统性红斑狼疮临床实践指南2025更新:基于GRADED的拉美地区治疗推荐
GLADEL–PANLAR clinical practice guidelines for the management of systemic lupus erythematosus: 2025 update
GLADEL与PANLAR联合发布的系统性红斑狼疮(SLE)临床实践指南2025年更新,基于2018年以来66项新RCT和网络Meta分析,提出13条推荐和10条良好实践声明。
拉丁美洲首个针对区域流行病学和医疗可及性制定的SLE临床实践指南更新,纳入2018年以来新疗法证据。
Introduction
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with multisystem involvement, often characterized by a relapsing-remitting course and a high burden of organ damage, impaired quality of life and adverse long-term outcomes1,2,3. The disease arises from the interplay of genetic, epigenetic, hormonal and environmental factors4,5,6,7,8, resulting in a wide spectrum of clinical manifestations and disease severity across racial and ethnic groups and socioeconomic statuses1,9,10.
Latin America and the Caribbean represent a highly heterogeneous region encompassing 33 countries and over 650 million inhabitants, characterized by a diverse population comprising people of European descent, Mestizo populations (people of Native American and European ancestry), people of African descent and Indigenous communities. Patients of Mestizo ancestry can exhibit distinct patterns of SLE, including earlier disease onset, a greater frequency of kidney involvement and a more severe overall disease course1. In parallel, profound socioeconomic status disparities, delayed diagnosis and limited access to rheumatology care, diagnostic tools and advanced therapies contribute to worse outcomes across the region compared with those reported in some populations in Europe and the USA2,11,12,13. These intersecting biological and social determinants of health highlight the need for region-specific clinical practice guidelines for the treatment of SLE, tailored to the epidemiological profile and health care realities of Latin America. Implementation in the region must consider not only scientific evidence, but also contextual challenges such as poverty, limited access to education, restricted availability of specialized care and fragmented health care systems. Although these factors do not alter the underlying evidence-based recommendations, they might substantially influence their feasibility and implementation in clinical practice.
In response to these challenges, the Latin American Group for the Study of Lupus (Grupo Latino Americano De Estudio del Lupus (GLADEL)) and the Pan American League of Associations for Rheumatology (PANLAR) developed and published the first region-specific clinical practice guidelines for the treatment of SLE in 2018 (refs. 14,15). Since then, several therapies have been approved for new indications and others have demonstrated efficacy in phase III trials, expanding the therapeutic armamentarium and reshaping the management of SLE.
Building on the prespecified population, intervention, comparator and outcomes (PICO) questions, these 13 recommendations, complemented by ten good practice statements, address key clinical scenarios in SLE management through a rigorous, independent, evidence-based process. Although the 13 recommendations addressing the ten predefined PICO questions are broadly consistent with contemporary guidelines from the European Alliance of Associations for Rheumatology (EULAR), American College of Rheumatology (ACR) and Kidney Disease: Improving Global Outcomes (KDIGO)16,17, they provide a Latin American perspective by explicitly considering regional needs, feasibility, equity, access to care, patient values and implementation challenges.
These guidelines emphasize a shift towards treat-to-target (T2T) strategies, earlier integration of biologic drugs and targeted therapies into treatment algorithms and strategies to minimize glucocorticoid exposure through early tapering and glucocorticoid-sparing approaches. These recommendations are primarily based on evidence from adult patients with SLE, although paediatric considerations are addressed where relevant. They are intended to support health care professionals involved in the care of patients with SLE across diverse clinical settings and to complement, rather than to replace, clinical judgement. Shared decision making remains paramount. Although primarily focused on clinical care, they might also inform health policy and decision making aimed at improving access to optimal SLE management in the Latin American region.
This document updates the 2018 GLADEL–PANLAR guidelines for the treatment of SLE14,15 and provides evidence-based recommendations developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework for organ-specific and scenario-based management18. It incorporates evidence published since 2016 (as the evidence base underpinning the 2018 guidelines included only studies published up to and including 2015) including new randomized controlled trials (RCTs) and network meta-analyses conducted for relevant clinical questions (Supplementary Box 1)19,20 and reflects an expanded therapeutic armamentarium, including conventional immunosuppressive and biologic therapies. The recommendations integrate evidence from a systematic review (Supplementary Table 1), the original evidence base from the 2018 guidelines where applicable, patient values and preferences and the expertise of a multidisciplinary panel including adult and paediatric rheumatologists, internists, nephrologists and dermatologists.
Methods
These clinical practice guidelines for the treatment of SLE were developed by GLADEL and PANLAR and constitute an update to the original Latin American recommendations for the treatment of SLE published in 2018 (ref. 14). The guideline panel used a structured, transparent and evidence-based process aligned with internationally accepted standards for trustworthy guideline development. The methodology followed the Institute of Medicine21 and Reporting Items for Practice Guidelines in Healthcare22 standards and met all criteria established by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group for the development of high-quality clinical practice guidelines18.
The core leadership group (Supplementary Table 2) drafted the PICO questions and coordinated the overall project. The methodology group, composed of experts in evidence synthesis and the GRADE approach, led the development of the systematic review and network meta-analyses (Supplementary Box 1). They guided the panel through the interpretation of evidence, construction of evidence profiles and the use of the evidence-to-decision frameworks. The guideline panel consisted of 58 clinicians with expertise in SLE from 11 countries across Latin America (Argentina, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Mexico, Paraguay, Peru, Uruguay and Venezuela). The recommendations were subsequently reviewed by experts from five countries worldwide (China, France, Ghana, Greece and the USA), including adult and paediatric rheumatologists, nephrologists, dermatologists and internists, representing both GLADEL and PANLAR (Supplementary Table 2). Panellists were selected based on clinical experience and regional representation to ensure diversity of perspectives and practice settings. Several members participated in the original guidelines, ensuring continuity and institutional knowledge. To ensure comprehensive coverage of SLE manifestations, the panel was further organized into expert working groups according to organ or system domains (Supplementary Table 2).
Before conducting the systematic reviews, the guideline panel defined all clinical questions using the PICO framework. These questions formed the basis for the systematic reviews, evidence synthesis and subsequent GRADE evidence-to-decision assessments (Supplementary Tables 3–7). The exact wording of the predefined PICO questions is provided in Supplementary Table 11.
Patients were involved at multiple stages of the guideline development process to ensure that the recommendations reflect outcomes and trade-offs that matter most to individuals living with SLE. As part of the guideline development process, 28 patients from across Latin America were asked about their perspectives on the importance of various clinical outcomes and on what constitutes meaningful benefit or harm. Participants were not selected to be nationally representative by country or population density; rather, they comprised patients who were willing and able to contribute their perspectives to the guideline process. These patient perspectives informed the prioritization of outcomes in the GRADE evidence profiles and helped to derive quantitative thresholds that defined the magnitude of treatment effects, specifically what patients considered to be small, moderate or large benefits and harms23.
As this project represents an update of the 2018 GLADEL–PANLAR guideline rather than de novo guideline development, the evidence synthesized for the original recommendations remained part of the evidentiary foundation of the current process, where applicable. The original guideline incorporated evidence from both RCTs and observational studies, particularly for uncommon manifestations for which RCT evidence was unavailable. For the present update, the systematic review prioritized the identification of RCTs published since 2016, with searches updated through 28 February 2025 as these studies were considered most likely to modify treatment-effect estimates, increase certainty in the evidence or change existing recommendations. For all PICO questions, members of each organ-specific expert group were invited, both before and during the recommendation-development meetings, to identify relevant observational studies, open-label trials or other evidence not captured by the RCT-focused systematic review that could materially affect the interpretation of the evidence or the formulation of a recommendation, but no additional studies were identified through expert input. The guideline panel evaluated the updated evidence together with the original evidence base, where applicable, and current considerations within the GRADE evidence-to-decision framework. Recommendations for which the updated evidence did not warrant a substantive change were retained.
In several clinical scenarios with multiple therapeutic options, particularly for moderate-to-severe SLE and the initial and subsequent treatment of lupus nephritis, a network meta-analysis was performed. Unlike conventional meta-analyses, network meta-analyses enable the simultaneous comparison of all available interventions by integrating both direct evidence from RCTs and indirect evidence through common comparators, providing a comprehensive view of the therapeutic landscape. This approach enabled the panel to assess the relative effects of all available treatments within the same analytical framework and to better inform comparative decision making. We used the GRADE approach to synthesize the evidence on intervention effects and to assess the certainty of the evidence for each critical and important outcome. For the clinical questions addressed by network meta-analysis, summary-of-findings tables (Supplementary Tables 8–10) were constructed, presenting the effect estimates, confidence intervals and GRADE certainty ratings (high, moderate, low or very low). These tables were reviewed by the organ-specific expert groups during the evidence-to-decision process. Further details regarding the analytical framework applied across all the network meta-analyses are provided in Supplementary Box 1. A detailed application of this common analytical framework is available in a separate open-access publication reporting the network meta-analyses of initial treatments for lupus nephritis19.
A total of four recommendation–development meetings were held virtually between 18 December 2024 and 4 June 2025. No formal Delphi process was used. For each clinical question, the methodology group presented the corresponding summary-of-findings table and GRADE evidence-to-decision framework. The panel then deliberated on the relevant evidence-to-decision criteria and the direction, strength and wording of each recommendation. The panel first sought to achieve consensus through structured discussion. When consensus could not be reached, a formal vote was conducted. Abstentions were permitted, and a minimum agreement of 70% among members who voted on the PICO question, excluding abstentions, was required for a recommendation to be adopted. The strength of each recommendation (strong or conditional) was determined according to the GRADE framework and the evidence-to-decision judgements made by the guideline panel, rather than the percentage of agreement in the vote.
The systematic literature searches were not restricted by age; RCTs that enrolled adults, children or adolescents were eligible. Age was considered a potential effect modifier within the prioritized clinical questions rather than the basis for separate paediatric PICO questions. However, evidence from paediatric populations was sparse and insufficient to assess whether age modified treatment effects or to construct paediatric-specific evidence profiles. Consequently, considerations and recommendations pertaining to children and adolescents in this guideline are based primarily on indirect evidence extrapolated from adult populations. Detailed summaries of the evidence considered during the guideline development process are available in Supplementary Tables 3–10.
Ultimately, 66 new RCTs met the eligibility criteria and were incorporated into the updated review (Supplementary Fig. 1). Supplementary Table 1 lists the studies informing the five updated recommendation statements, including previously available studies (that is, studies included in the 2018 guidelines) where applicable. Four conference abstracts were included on an exceptional basis as they provided relevant outcome data; otherwise, conference abstracts were not routinely considered sources of evidence. In addition, a complete evidence repository is available online20, with the evidence organized according to the corresponding PICO question and treatment comparison.
For each PICO question, the panel used GRADE evidence-to-decision frameworks (Supplementary Tables 3–7) to translate the evidence into recommendations addressing ten clinical questions (Supplementary Table 11). The frameworks integrated data on benefits and harms, certainty of the evidence, resource use, equity, feasibility and acceptability. Panel deliberations followed a structured and transparent process, and recommendations were formulated. Panel composition and deliberation processes prioritized equity, diversity and inclusion, with particular attention given to regional health disparities and social determinants of health. For each clinical scenario, interventions evaluated within the GRADE evidence-to-decision framework but not included among the recommended treatment options were conditionally recommended against. The rationale underlying these judgements, including the balance of benefits and harms, certainty of the evidence, resource requirements, feasibility, acceptability and equity is summarized in the corresponding evidence-to-decision tables provided in Supplementary Tables 3–7.
Implementation considerations were included for each evidence-based recommendation developed using the GRADE methodology. These considerations reflect the applicability and contextual adaptation of the recommendations in real-world settings in Latin America. In addition, the guideline panel developed and agreed upon ten good practice statements24. These statements were formulated based on widely accepted principles of care and refined and agreed upon through iterative discussions within the panel.
Good practice statements
The guideline panel agreed upon ten good practice statements24. These statements provide a framework to guide clinical decision making and support consistent, equitable and context-adapted care across diverse health care settings in Latin America. The statements are presented below with supporting explanations and are also summarized in Box 1.
Statement 1. Early diagnosis and early treatment
Early diagnosis of SLE is a prerequisite for implementing T2T strategies and preventing irreversible organ damage. Delayed recognition is associated with higher disease activity, prolonged glucocorticoid use, greater damage accrual and poorer long-term outcomes5,25,26,27. Current classification criteria28 are intended for research purposes and should not be used as diagnostic criteria, as reliance on them can delay clinical diagnosis and treatment initiation. Clinical judgement and expertise, supported by appropriate laboratory evaluation and early specialist assessment when available, remain central to SLE diagnosis.
Statement 2. Treat-to-target strategy
Management of SLE should be based on regular and systematic monitoring of disease activity, cumulative organ damage and treatment toxicity within a T2T framework29. The primary therapeutic goal should be remission or, when remission is not achievable, low disease activity, with periodic reassessment of treatment targets using established definitions, including DORIS (definition of remission in SLE) and the LLDAS (lupus low disease activity state)30,31. Following treatment initiation or modification, response should generally be reassessed within approximately 3 months, or earlier in severe disease. Lack of meaningful improvement, worsening disease or inability to reduce glucocorticoid exposure should prompt treatment optimization or modification. Timing should be individualized according to organ involvement, severity and expected response to treatment. When remission is achieved, sustained remission should be considered the optimal long-term goal. Standardized instruments, such as the SLE Disease Activity Index 2000 for disease activity and the SLICC–ACR Damage Index for cumulative organ damage32,33 and the Physician Global Assessment34, should be used to support disease monitoring and timely treatment adjustments, with the aim of reducing flares, limiting irreversible organ damage and decreasing hospitalizations. A T2T approach also supports glucocorticoid-sparing strategies to avoid overuse. In addition to controlling disease activity, management should address factors that affect health-related quality of life, including fatigue, pain and depression.
Statement 3. Patient-centred care and shared decision making
Therapeutic decisions should incorporate patient values, preferences and expectations, recognizing the chronic and heterogeneous nature of the SLE. Effective communication and structured patient education are essential to support adherence and sustained engagement in long-term care.
Statement 4. Multidisciplinary and coordinated care
Optimal management of SLE requires structured, coordinated and multidisciplinary care owing to its multisystem and chronic nature. Clear referral pathways and collaborative health care networks among rheumatologists, nephrologists, dermatologists, primary care physicians and other health professionals are essential to ensure timely access to specialized care. Primary care physicians have a key role, not only in the long-term monitoring of patients with SLE but also in the early recognition of suspected disease and timely referral to a rheumatologist. They also contribute to the management of comorbidities, vaccination and support treatment adherence. Educational initiatives and practical tools for frontline clinicians and other involved specialties, such as the GLADEL ¿Es Lupus? (Is it Lupus?) program, should be encouraged to strengthen shared management across levels of care.
Statement 5. Prevention of infections and vaccination
Vaccination status should be regularly assessed and updated in patients with SLE according to national immunization programmes and international recommendations, including influenza, tetanus–diphtheria–pertussis, pneumococcal, COVID-19, hepatitis B, human papillomavirus (HPV) and herpes zoster vaccines35,36,37,38. Vaccination strategies should preferably be implemented during periods of disease stability and before initiation of intensive immunosuppressive therapies; however, vaccination should not be unnecessarily delayed when clinically indicated. Live-attenuated vaccines, such as yellow fever, Argentine haemorrhagic fever and dengue vaccines, are generally not recommended for patients who are immunosuppressed, and each case should be individually assessed according to the risk–benefit profile of the patient. Additionally, infection risk and the presence of chronic infections, such as tuberculosis, HIV, hepatitis B and hepatitis C, should be assessed before treatment initiation. Endemic infections prevalent in Latin America, such as dengue virus, Zika virus, chikungunya virus and Chagas disease, should be considered on an individual basis according to the epidemiological context and patient characteristics.
Statement 6. Long-term surveillance for comorbidities, cardiovascular risk and malignancies
Long-term SLE care should include prevention, surveillance and management of comorbidities and malignancies. The disease itself, chronic inflammation, cumulative organ damage, prolonged glucocorticoid exposure and immunosuppressive therapies increase the risk of cardiovascular disease, osteoporosis and cancer. Cardiovascular risk factors, including hypertension, dyslipidaemia, diabetes and obesity, should be routinely assessed and controlled. Malignancy screening should follow population-based recommendations, with additional vigilance for skin cancer, HPV-related neoplasia and suspected haematological malignancy in patients receiving long-term immunosuppression.
Statement 7. Promotion of healthy lifestyle, photoprotection and patient education
Promotion of a healthy lifestyle is a fundamental principle in the comprehensive management of SLE. Patients should be encouraged to engage in regular physical activity, avoid smoking, maintain a balanced diet and achieve a healthy body weight according to individual capacity and disease status. Smoking is of particular concern in patients with SLE, as it contributes to comorbidities and is associated with poorer disease control and reduced therapeutic response to key treatments, including antimalarials and biologic agents such as belimumab39. Exposure to ultraviolet radiation can trigger or exacerbate cutaneous and systemic disease activity. Patients should receive regular counselling on effective photoprotection strategies, including sun avoidance, protective clothing and appropriate use of sunscreen. Patient education should address disease understanding, treatment adherence and recognition of disease flares. Programmes such as Hablemos de Lupus (Talking about Lupus) from GLADEL and patient organizations are valuable resources for supporting patient education and empowerment.
Statement 8. Use of antimalarials
Antimalarials, such as hydroxychloroquine or chloroquine, should be used in all patients with SLE unless contraindicated, as they reduce disease activity, prevent flares, limit damage accrual and improve survival. The recommended daily dose should not exceed 5 mg/kg per day of actual body weight for hydroxychloroquine and 2.3 mg/kg per day for chloroquine to minimize the risk of retinal toxicity. Dosing should be individualized according to disease activity, risk of flares and retinal toxicity. In selected patients with severe disease, a temporary hydroxychloroquine dose above 5 mg/kg per day could be considered following an individualized assessment of benefit and risks, under close safety monitoring, with dose reduction once disease control is achieved. Current evidence and international guidelines recommend a baseline ophthalmic examination within the first year of starting chloroquine or hydroxychloroquine treatment to rule out pre-existing maculopathy. In the absence of major risk factors, annual screening should begin only after 5 years of continuous therapy. More frequent monitoring is reserved exclusively for patients with high-risk features, such as daily overdosing, renal impairment, concomitant tamoxifen use or pre-existing retinal disease40,41. Measurement of hydroxychloroquine levels in plasma might be a useful tool to assess adherence and guide dose optimization in selected patients. However, given its limited availability across most Latin American countries, routine monitoring cannot currently be recommended as a standard component of care. As a higher frequency of retinal events has been described with chloroquine42, hydroxychloroquine should be preferred. A baseline electrocardiogram should also be considered, particularly in patients at risk of QT interval prolongation or receiving concomitant QT interval-prolonging medications. Current evidence does not support routine discontinuation of antimalarials based solely on treatment duration; long-term therapy is generally recommended.
Statement 9. Rational and safe use of glucocorticoids
Glucocorticoids remain an important component of SLE management but are also a major contributor to long-term organ damage. In Latin America, their use remains widespread because of their accessibility, relatively low cost and the frequent occurrence of severe disease presentations. Glucocorticoids, if clinically indicated, should be used at the lowest effective dose and for the shortest possible duration, with rapid tapering whenever clinically feasible, while immunosuppressive or biologic agents take effect (typically within 6 months) and aiming for discontinuation when possible. When clinically indicated, intravenous methylprednisolone pulses, including lower-dose regimens of 125–500 mg per day for 1–3 days, might be considered to achieve rapid disease control while limiting long-term toxicity. Doses of up to 1,000 mg per day can be used for exceptional, life-threatening manifestations. Failure to taper glucocorticoids or persistent dependence should prompt reassessment of the therapeutic strategy.
Statement 10. Pregnancy planning and management
Women with SLE can have successful pregnancies; however, careful planning is essential. Pregnancy should be planned during periods of remission, ideally after at least 6 months of sustained disease stability. Preconception counselling should include assessment of autoantibody status (antiphospholipid, anti-Ro and anti-La antibodies), discontinuation of teratogenic medications and optimization of pregnancy-compatible therapies. Although active disease, particularly active lupus nephritis or impaired kidney function, represents a relative contraindication and should prompt postponement of pregnancy, other factors should also be considered when determining the optimal timing for conception. Close multidisciplinary follow-up, involving rheumatology and high-risk obstetric care, is essential to optimize maternal and foetal outcomes.
Recommendations
This section presents the 13 recommendations agreed upon by the voting panel (Table 1). These recommendations are intended as clinical practice guidance rather than inflexible rules and their implementation might be constrained by access to health care services, diagnostics, specialists and medications. When barriers exist, reasonable, context-adapted alternatives should be considered. Throughout these guidelines, clinicians should also consider key patient-level determinants of outcomes and feasibility, such as ethnicity, educational level, health literacy, socioeconomic status and place of residence (urban or rural and distance to care), as these factors influence access, adherence and response to treatment.
For each PICO question, the panel evaluated therapeutic interventions based on the balance between benefit and harm, certainty of the evidence, patient values and preferences, local availability, cost, feasibility and implementation considerations. Building on the 2018 recommendations, the panel considered antimalarials (including hydroxychloroquine or chloroquine) as universal background therapy for patients with SLE unless contraindicated, whereas glucocorticoids should be used at the lowest effective dose and for the shortest possible duration, with tapering as early as feasible. Conventional immunosuppressive therapies, including methotrexate, leflunomide and azathioprine, as previously outlined in the 2018 guidelines, remain part of the therapeutic backbone for selected patients with SLE, particularly for those with persistent disease manifestations despite treatment with antimalarials with or without glucocorticoids, depending on disease severity, organ involvement and clinical features. In patients with lupus nephritis, mycophenolic acid analogues (MPAAs), including mycophenolate mofetil and mycophenolic acid, were used as the main comparator for evaluating other interventions, as most of the available evidence for both initiation and subsequent therapy is derived from their use. The selection of MPAAs as the main comparator reflects their role as a key component of the conventional immunosuppressive backbone in clinical practice and their widespread use as background treatment in clinical trials. However, intravenous cyclophosphamide remains commonly used as a first-line induction therapy in routine care and has also been evaluated in selected clinical trial populations, including in combination with biologic agents. Doses and implementation considerations for adult and paediatric patients are described in Table 2.
No new high-quality evidence was identified to warrant modification of the recommendations for cardiac, pulmonary, neuropsychiatric and haematological manifestations. Owing to the lack of data on efficacy and concerns regarding costs, feasibility, acceptability and equity, the panel did not include additional therapeutic options in these domains. Therefore, the recommendations remain unchanged from the 2018 GLADEL–PANLAR guidelines; the full rationale for these recommendations has been previously published14. Accordingly, the unchanged recommendations are presented here together with a concise summary of their rationale and considerations for implementation. The recommendations presented in this section should be implemented through individualized and shared decision making. Treatment selection should consider disease severity and rate of progression, predominant organ manifestations, previous therapies and response, comorbidities, risk of infection, reproductive considerations, treatment burden, monitoring requirements and the availability, feasibility and cost of therapies within the local health care setting. These overarching implementation considerations apply to all recommendations unless otherwise specified. Fig. 1 illustrates the schematic overview of the GLADEL–PANLAR treatment framework for SLE.
This figure presents a schematic overview of the Latin American Group for the Study of Lupus–Pan-American League of Associations for Rheumatology treatment framework for patients with SLE. In patients with active SLE, treatment is guided by organ involvement and disease activity and severity, with the aim of achieving remission or, when remission is not achievable, low disease activity. Once remission is achieved, sustained remission represents the optimal long-term goal, together with progressive minimization of glucocorticoid exposure and, whenever clinically feasible, glucocorticoid discontinuation. The good practice statements provide the foundation of care and apply throughout all stages of disease management. Treatment selection should be individualized according to organ involvement, disease activity and severity, previous treatment and response, comorbidities, reproductive considerations, patient preferences and other relevant clinical factors, while also being adapted to the local context, including availability, feasibility, monitoring capacity, cost and equity. Importantly, combination strategies and biologic drugs and/or targeted therapies can be incorporated as part of initial treatment when appropriate and are not restricted to refractory disease or previous treatment failure. Contextual constraints can influence the strategy used to achieve therapeutic goals but should not redefine the goals themselves. This principle of context-adapted care is applicable across health care settings in which access, resources or implementation constraints influence treatment delivery, irrespective of geographical region. Time is an integral component of the framework. Response should be reassessed periodically after treatment initiation or modification, at intervals appropriate to the clinical scenario and expected response. Lack of meaningful improvement, worsening disease or inability to reduce glucocorticoid exposure should prompt treatment reassessment and optimization, avoiding therapeutic inertia and prolonged glucocorticoid dependence. Treatment optimization is continuous: when the therapeutic target is not achieved, treatment should be intensified, modified or switched as appropriate; when adequate disease control is achieved, optimization includes maintaining effective disease control while progressively tapering glucocorticoids, with discontinuation whenever clinically feasible.
Recommendation 1
For adult patients with SLE and mild musculoskeletal or cutaneous manifestations, the panel conditionally recommends antimalarials with or without glucocorticoids, with or without conventional immunosuppressive therapy, rather than adding biologic or targeted therapies (new recommendation; conditional recommendation; moderate-to-high certainty of evidence).
Summary of rationale
This approach differs from the 2018 guidelines as the reformulated PICO question stratifies patients into mild and moderate-to-severe musculoskeletal and/or cutaneous disease (Box 2), enabling a more time-sensitive escalation strategy, consistent with the concept of an early window of opportunity in which prompt therapeutic intervention might modify disease trajectory and improve long-term outcomes.
Overall, in adults with mild musculoskeletal and/or cutaneous SLE, the balance of benefits, harms and resource use favours antimalarials with or without glucocorticoids, with or without conventional immunosuppressive therapy, without early introduction of biologic or targeted therapies (Supplementary Table 3). This approach is consistent with a T2T framework and supports early tapering of glucocorticoids to minimize unnecessary exposure. Although several advanced therapies have demonstrated efficacy in RCTs43,44, these studies have largely enrolled patients with moderate-to-severe disease (Supplementary Table 8); therefore, the lower baseline risk of damage and disability in mild SLE translates into smaller absolute benefits from early escalation.
Antimalarials with or without glucocorticoids, with or without conventional immunosuppressive agents when clinically indicated, have a well-established efficacy and safety profile and provide adequate disease control for many patients with mild inflammatory activity. The clinical heterogeneity of mild disease is also relevant, as persistent symptoms can arise from non-inflammatory or post-inflammatory mechanisms, thereby limiting the expected added benefit of early escalation.
Importantly, these guidelines were developed for application in Latin America, where access to biologic drugs and targeted therapies is variable and often constrained; in this setting, prioritizing effective, widely available and lower-cost therapies represents a more efficient and equitable use of health care resources.
Considerations for implementation
Antimalarials should be prescribed to every patient with SLE, unless contraindicated, as universal background therapy. Glucocorticoids should be used at the lowest effective dose and for the shortest possible duration, with tapering as early as feasible. In selected clinical scenarios, even in patients with mild SLE, initiation of a conventional immunosuppressive therapy as part of the initial regimen should be considered when there is substantial disease activity, contraindication or intolerance to antimalarials or when glucocorticoids cannot be successfully tapered and discontinued. Options include methotrexate, leflunomide, azathioprine and MPAAs. The type and dose of conventional immunosuppressive therapy should be established according to SLE manifestations, severity, patient preferences, comorbidities, risk of infection, reproductive considerations, tolerability and access. Disease activity should be monitored periodically using a reproducible assessment tool (such as the SLE Disease Activity Index 2000 (ref. 32)), the Cutaneous Lupus Erythematosus Disease Area and Severity Index45, the Physician Global Assessment34 together with patient-reported outcomes and supported by shared decision making.
For musculoskeletal involvement, clinicians should confirm objective evidence of inflammatory activity (for example, synovitis or tenosynovitis, inflammatory-pattern pain and stiffness, elevation of acute-phase reactants and/or imaging findings), differentiate from non-inflammatory pain mechanisms and optimize non-pharmacological and symptom-directed measures (including short courses of NSAIDs when appropriate and safe). In this scenario, among patients with persistent disease activity despite antimalarial therapy, methotrexate is commonly used as a first-line conventional immunosuppressive therapy, followed by leflunomide.
For cutaneous disease, including acute, subacute and chronic manifestations, systemic therapy with antimalarials with or without glucocorticoids, with or without conventional immunosuppressive therapy when clinically indicated should be aligned with appropriate topical therapy selected according to site and phenotype. When topical glucocorticoids are used, the lowest effective potency should be selected, particularly for the face and intertriginous areas, to reduce the risk of skin atrophy. When feasible, interdisciplinary management with dermatologists is recommended. Clinicians should distinguish active inflammatory lesions from skin damage, for which further immunosuppression is unlikely to be beneficial.
If clinically relevant inflammatory activity in the joints and/or skin persists beyond 12 weeks despite an appropriate initial regimen, treatment adherence should be confirmed and non-inflammatory or damage-related causes should be excluded. Treatment should then be optimized or escalated according to the moderate-to-severe disease pathway as appropriate. Persistent inflammatory disease despite optimized therapy might be considered refractory29,30.
Recommendation 2
For adult patients with SLE and moderate-to-severe musculoskeletal manifestations, the panel conditionally recommends adding belimumab or anifrolumab to antimalarials with or without glucocorticoids, with or without conventional immunosuppressive therapy (updated recommendation; conditional recommendation; moderate-to-high certainty of evidence).
Recommendation 3
For adult patients with refractory musculoskeletal SLE, the panel conditionally recommends adding rituximab to antimalarials with or without glucocorticoids, with or without conventional immunosuppressive therapy (updated recommendation; conditional recommendation; low certainty of evidence).
Recommendation 4
For adult patients with SLE and moderate-to-severe cutaneous manifestations, the panel conditionally recommends adding belimumab or anifrolumab to antimalarials with or without glucocorticoids, with or without conventional immunosuppressive therapy (updated recommendation; conditional recommendation; moderate-to-high certainty of evidence).
Summary of rationale
The recommendations for moderate-to-severe musculoskeletal and cutaneous manifestations differ from the 2018 guidelines, reflecting the emergence of new therapies and evidence. These conditional recommendations are supported by a favourable benefit–risk balance and moderate-to-high certainty of evidence showing that belimumab and anifrolumab improve musculoskeletal and cutaneous disease manifestations and overall disease activity in adults with moderate-to-severe SLE (Supplementary Table 8). In this population, the absolute benefit of adding biologic therapy to antimalarials with or without glucocorticoids, with or without conventional immunosuppressive therapy, is greater than in mild disease, given the higher inflammatory burden, increased risk of functional impairment and irreversible damage and the greater likelihood of glucocorticoid dependence if effective treatment is delayed.
In the absence of head-to-head clinical trials, the panel does not express a preference between belimumab and anifrolumab. The effects of these interventions across the outcomes of interest are summarized in Supplementary Tables 4 and 5. Optimizing antimalarial therapy with or without glucocorticoids, with or without conventional immunosuppressive therapy and appropriate topical measures, is often insufficient in this population, and persistent disease activity might result in cumulative glucocorticoid exposure and sustained impairment in health-related quality of life.
Deucravacitinib has demonstrated promising efficacy; however, the panel judged that the certainty of evidence, particularly regarding long-term safety outcomes in patients with SLE, remains insufficient to support its routine use in this setting. Rituximab was considered as an option for refractory disease, particularly for the treatment of musculoskeletal involvement, despite low-certainty evidence from RCTs, on the basis of consistent clinical experience and supportive observational data. Its role in cutaneous disease was not prioritized owing to the lack of consistent evidence from trials.
Importantly, these guidelines were developed for Latin American settings, where access to biologic drugs and targeted therapies is heterogeneous; therefore, feasibility, availability and cost were integral to the assessment of net benefit, as these factors might limit timely access to these therapies. Overall, the evidence suggests that adding selected biologic therapies to antimalarials with or without glucocorticoids, with or without conventional immunosuppressive therapy, provides meaningful clinical benefit in moderate-to-severe musculoskeletal and cutaneous SLE. These contextual constraints are reflected in the conditional strength of these recommendations.
Considerations for implementation
Most patients with active moderate-to-severe musculoskeletal and/or cutaneous disease (acute, subacute or chronic) are likely to benefit from combination therapy with belimumab or anifrolumab added to antimalarials with or without glucocorticoids, with or without conventional immunosuppressive therapy, using a time-anchored, stepwise approach within a T2T framework aiming for remission or low disease activity29,46. The trials informing these recommendations evaluated belimumab and anifrolumab as add-on therapies to heterogeneous background treatment46 (Supplementary Table 1). Accordingly, neither concomitant conventional immunosuppressive therapy nor prior failure of such therapy is required before adding belimumab or anifrolumab to antimalarials, with or without glucocorticoids. However, initial treatment with a conventional immunosuppressive therapy remains a reasonable alternative, depending on clinical characteristics, previous therapies, safety considerations, patient preferences and local treatment availability. Additional factors such as glucocorticoid dependence, frequent relapses, substantial functional impairment or persistent reduction in quality of life despite appropriate therapy should also be considered when guiding treatment decisions.
Treatment selection should be individualized and guided by the overall SLE phenotype, comorbidities, patient preference and local feasibility. Belimumab has been available in Latin America for longer than anifrolumab, offers both intravenous and subcutaneous formulations and has a well-established long-term safety profile. A history of mood disorders, including depression and suicidal ideation, should be assessed before initiating belimumab and monitored periodically throughout treatment47,48.
Anifrolumab is currently available only as an intravenous formulation in Latin America; however, a subcutaneous formulation has been evaluated in a phase II safety study49 and a phase III efficacy and safety trial50, showing efficacy consistent with the intravenous route. This formulation has been approved by regulatory agencies in selected regions, including the European Union, Canada and the USA. Anifrolumab has a relatively rapid onset of action and demonstrates efficacy across multiple SLE domains, particularly skin manifestations. Regarding safety, an increased risk of herpes zoster has been observed51.
The management of refractory discoid lupus or lupus panniculitis, which can cause permanent scarring, dyspigmentation and alopecia, might require a more individualized approach. Treatment options include topical or intralesional glucocorticoids, methotrexate or thalidomide, followed by belimumab or anifrolumab for refractory disease. For hypertrophic lupus or bullous lupus, retinoids or dapsone might also be considered. Rituximab should be reserved for refractory musculoskeletal SLE, particularly when other systemic manifestations support its use52,53.
Measures for rapid disease control should be considered, including the use of glucocorticoids with early tapering and rational use of analgesics and NSAIDs. Non-pharmacological strategies should be integrated early and consistently, including rehabilitation and graded exercise, optimization of sleep and management of comorbidities such as obesity and mood disorders29,46. Figure 2 provides the management algorithm for musculoskeletal and cutaneous manifestations.
This algorithm outlines a treat-to-target (T2T) approach for adult patients with systemic lupus erythematosus (SLE) presenting with musculoskeletal (MSK) and/or cutaneous manifestations, aiming to achieve remission or low disease activity state (LDAS). After confirming inflammatory disease activity and excluding non-inflammatory mechanisms, patients are stratified according to disease severity. In patients with mild disease, antimalarials ± glucocorticoids are recommended, with consideration of conventional immunosuppressive therapies (methotrexate, leflunomide, azathioprine and mycophenolic acid analogues (MPAAs)) in selected cases. Early use of biologic or targeted therapies is not recommended in this group. In patients with moderate-to-severe disease, the addition of biologic therapy (belimumab or anifrolumab) to antimalarials ± glucocorticoids, with or without conventional immunosuppressive therapies, is recommended. Initial treatment with a conventional immunosuppressive therapy remains a reasonable strategy in selected patients, according to clinical characteristics, previous therapies, safety considerations, patient preferences and local availability of treatment. Response to treatment should be assessed after approximately 12 weeks or earlier for severe disease. If the therapeutic target is achieved, treatment should continue with progressive glucocorticoid tapering. In cases of persistent inflammatory activity despite adequate therapy and adherence, after excluding damage or non-inflammatory causes, treatment optimization or escalation is recommended. For refractory musculoskeletal disease, rituximab (RTX) might be considered. For refractory cutaneous disease, phenotype and inflammatory activity should be reassessed and therapy optimized or switched. Supportive therapy should be integrated at all stages and includes symptom-directed pharmacological treatment, rehabilitation, topical therapies for cutaneous disease, lifestyle measures (including smoking cessation, diet, exercise and weight control), vaccination and management of comorbidities.
Recommendation 5
For adult patients with SLE and active proliferative lupus nephritis (ISN–RPS class III or IV lupus nephritis, with or without concomitant class V disease), the panel conditionally recommends antimalarials with glucocorticoids in combination with conventional immunosuppressive therapy, using one of the following regimens: a calcineurin inhibitor (CNI, voclosporin or tacrolimus) or obinutuzumab added to background therapy with MPAAs; or belimumab, which should be used in combination with either MPAAs or intravenous cyclophosphamide (updated recommendation; conditional recommendation, supported by high certainty of evidence for belimumab and voclosporin, moderate certainty for obinutuzumab and low certainty for tacrolimus).
Recommendation 6
For adult patients with SLE and proliferative lupus nephritis (ISN–RPS class III or IV lupus nephritis, with or without concomitant class V disease), once renal response has been achieved, the panel conditionally suggests subsequent therapy with antimalarials with or without glucocorticoids and MPAAs, in combination with either belimumab or obinutuzumab (updated recommendation; conditional recommendation; low certainty of evidence).
Summary of rationale
The updated conditional recommendations for initial therapy are supported by evidence demonstrating clinically meaningful improvements in key kidney outcomes when additional therapies are combined with the background regimens specified in Recommendation 5 for adults with active proliferative lupus nephritis (International Society of Nephrology–Renal Pathology Society (ISN–RPS) class III or IV, with or without concomitant class V disease), either at disease onset or during flares. These findings support the concept of an early window of opportunity, in which prompt initiation of combination therapy might improve kidney outcomes, reduce cumulative organ damage and modify the long-term disease trajectory. High-certainty evidence shows that the addition of belimumab or voclosporin to antimalarials with glucocorticoids and conventional immunosuppressive therapy improves complete and overall renal response, whereas moderate-certainty evidence supports similar benefits with obinutuzumab54 (Supplementary Table 9). These findings build on established background regimens comprising glucocorticoids combined with MPAAs or intravenous cyclophosphamide, according to the treatment strategy. Together, these results support the early use of combination therapy, including biologic agents or CNIs added to conventional immunosuppressive regimens, to enhance renal responses in proliferative lupus nephritis.
Although the certainty of evidence supporting tacrolimus as part of combination therapy is low, the panel considered its inclusion justified given its established use in lupus nephritis, lower cost and broader availability across many Latin American health care systems, although regulatory approval has not yet been granted in some countries. The panel conditionally recommended against the routine use of rituximab as an initial therapy for lupus nephritis, reflecting the very low certainty of the available evidence and the results of the LUNAR RCT53, which did not meet its primary end point. Nevertheless, rituximab might still be considered for refractory disease.
Following an initial renal response, this conditional recommendation for subsequent treatment is supported by evidence suggesting that the combination of selected biologic agents with antimalarials with or without glucocorticoids and MPAAs might reduce the risk of kidney relapse, maintain renal response and potentially slow long-term kidney function decline in patients with proliferative lupus nephritis55 (Supplementary Table 10). Although the certainty of evidence for individual agents is low overall, belimumab and obinutuzumab were considered to offer the most clinically meaningful potential benefit when added to MPAAs as part of subsequent therapy. Voclosporin was considered less suitable for long-term management given its high pill burden, limited evidence for prevention of kidney flares in this setting and concerns regarding prolonged CNI exposure, particularly in patients with established kidney damage56,57 (Supplementary Table 7).
Considerations for implementation
The management of lupus nephritis has evolved substantially since the publication of the 2018 guidelines driven by an expanding body of clinical trial evidence and the introduction of novel therapeutic strategies. In this context, the conventional distinction between ‘induction therapy’ and ‘maintenance therapy’ has become less clearly defined as combination strategies are increasingly implemented from the outset. Treatment can instead be framed as an initial intensive phase aimed at rapidly controlling kidney inflammation, followed by subsequent long-term therapy to consolidate response, prevent relapse and minimize cumulative glucocorticoid exposure.
Kidney biopsy remains essential to confirm the diagnosis and guide treatment decisions; however, when clinical suspicion is high and timely biopsy is not feasible, treatment should not be delayed17. Nevertheless, diagnosis based solely on proteinuria lacks precision for defining the histopathological class of lupus nephritis, and the degree of disease activity and chronicity.
Initial therapy for lupus nephritis includes antimalarials, intravenous glucocorticoid pulses followed by an individualized oral glucocorticoid regimen and taper, guided by Good Practice statement 9 and the practical considerations in Table 2, and background conventional immunosuppressive therapy with MPAAs or intravenous cyclophosphamide using either low-dose (according to the Euro-Lupus protocol) or high-dose (according to the NIH protocol) regimens58,59. For certain patients, combination therapy might include the addition of biologic agents or CNIs to this therapeutic backbone14,16,59. Treatment should be individualized according to renal and extra-renal manifestations, disease severity, comorbidities, reproductive plans, adherence, monitoring capacity, availability and clinical judgement. Early initiation of appropriate therapy is crucial to control inflammation, preserve kidney function and reduce the risk of irreversible organ damage, consistent with a T2T approach.
MPAAs are considered the preferred conventional immunosuppressive therapy for lupus nephritis, as most contemporary evidence on combination regimens has been generated using these agents for both initial and subsequent treatment. Their use is supported by a favourable efficacy and safety profile, including a lower risk of gonadal toxicity. Data from the Aspreva Lupus Management Study (ALMS) suggests that response to mycophenolate mofetil compared with cyclophosphamide might vary according to race, ethnicity and geographical region. Higher response rates were observed among Hispanic individuals, patients who enrolled in Latin America and participants categorized in the original study within the “other and Black subgroup”60; however, these findings have not been consistently validated in other cohorts. Cyclophosphamide remains a valid alternative for initial therapy, with comparable efficacy in achieving renal response, and might be preferred in selected scenarios, including for severe or organ-threatening disease, very active nephritis with crescents and/or fibrinoid necrosis, proliferative lupus nephritis with diffuse extracapillary proliferation, declining kidney function, concerns regarding adherence to oral therapy or when cost, access or feasibility limit the use of MPAAs. Depending on the clinical profile, two main regimens are used. The Euro-Lupus regimen is preferred for most patients with standard-risk disease to minimize cumulative cyclophosphamide exposure as this regimen has demonstrated comparable efficacy to high-dose treatment61,62. The high-dose NIH regimen is reserved for highly severe, rapidly progressive or refractory disease or when patient-specific factors warrant a more aggressive high-dose approach despite its higher toxicity profile63,64,65.
The selection of combination therapy should be individualized. Renal and extra-renal phenotypes, comorbidities, risk of infection, reproductive plans, prior therapies, monitoring capacity and local access should be considered. Belimumab in combination with MPAAs might be particularly appropriate for patients presenting with concurrent active renal and extrarenal disease, particularly those with proteinuria of <3 g per day and preserved kidney function (estimated glomerular filtration rate (eGFR) of ≥30 ml/min per 1.73 m2)54. In practice, subcutaneous administration is often preferred in adults owing to convenience and feasibility of home administration. The PLUTO trial provided evidence on the efficacy and safety of intravenous belimumab in children and adolescents (≥ 5 years of age) with SLE. This treatment has been approved for paediatric lupus nephritis in some jurisdictions based on extrapolation of efficacy data from adult lupus nephritis studies, supported by data from paediatric SLE populations66,67. Combination therapy might facilitate glucocorticoid minimization within a structured tapering strategy; however, tapering decisions should be individualized and guided by renal response and safety. In selected cases, depending on patient characteristics and access to medication, the combination of belimumab with cyclophosphamide could be considered54,57,68.
The addition of CNIs (such as voclosporin or tacrolimus) to antimalarials with or without glucocorticoids and MPAAs might be particularly beneficial in patients with class V lupus nephritis and/or nephrotic syndrome, as CNI-based combination therapy is associated with a faster decline in proteinuria and higher renal response rates63. In pregnant patients who require CNI therapy, tacrolimus or cyclosporine are preferred based on available safety evidence; fetal safety data for voclosporin remain limited. Voclosporin is not recommended in patients with a baseline eGFR ≤ 45 ml/min per 1.73 m2 unless the expected benefit exceeds the risk68,69. When initiating CNIs, clinicians should closely monitor serum creatinine, drug levels of CNIs (cyclosporin and tacrolimus) and blood pressure; adjustments might be required in the presence of clinically substantial increases in creatinine or worsening of hypertension. Once a stable dose has been achieved, therapeutic drug monitoring is recommended for tacrolimus but is not routinely required for voclosporin. Gastrointestinal tolerability and overall regimen complexity should be considered, particularly when higher-dose MPAAs are used concurrently. Although voclosporin has demonstrated efficacy in RCTs and is approved in the USA and Europe, access in Latin America remains limited and might be restricted to selected programmes.
Obinutuzumab in combination with MPAAs represents another therapeutic option that has been shown to improve renal response rates, including complete renal response with low-dose glucocorticoids70. These benefits have been observed in patients with proliferative lupus nephritis, including those with concomitant class V disease. Treatment requires infusion capacity and careful pre-treatment assessment. Infusion reactions can occur, and there might be an increased risk of infection; therefore, vaccination optimization, infection–risk mitigation and close clinical follow-up are essential57.
Important disparities in access to approved therapies for lupus nephritis persist across Latin America. In some settings, rituximab might be more accessible than newer agents despite the low certainty of supporting evidence. Therefore, in refractory disease, rituximab might be considered, balancing potential benefits, risks and local feasibility53. Alternative treatment strategies, including conventional immunosuppressive regimens, can be considered when access to preferred therapies is limited (Fig. 3).
This algorithm summarizes a treat-to-target strategy for adult patients with systemic lupus erythematosus and proliferative lupus nephritis (International Society of Nephrology–Renal Pathology Society (ISN–RPS) class III or IV lupus nephritis, with or without concomitant class V disease), aiming to achieve renal response and preserve long-term kidney function. Kidney biopsy is recommended to confirm diagnosis and guide treatment; however, treatment should not be delayed if biopsy is not feasible. Initial therapy consists of antimalarials plus intravenous glucocorticoid pulses followed by an oral glucocorticoid regimen and taper, in combination with background conventional immunosuppression using mycophenolic acid analogues (MPAAs, preferred) or intravenous cyclophosphamide in selected cases. In addition, one of the following combination strategies should be initiated: calcineurin inhibitor (CNIS, voclosporin or tacrolimus) or obinutuzumab added to MPAAs, or belimumab combined with either MPAAs or cyclophosphamide. When these combination therapies are contraindicated, not tolerated or access is limited, antimalarials + glucocorticoids + MPAAs or intravenous cyclophosphamide can be used as an alternative strategy. Response to treatment should be assessed at 12–24 weeks. Patients with complete renal response (CRR) or partial renal response (PRR) should transition to subsequent therapy, consisting of antimalarials + glucocorticoids plus MPAAs (backbone), in combination with belimumab or obinutuzumab, with progressive glucocorticoid tapering. When the therapeutic target is not achieved, treatment should be optimized or switched, with reassessment of adherence, disease phenotype and comorbidities. Rituximab should be considered for refractory disease. After transition to subsequent therapy or treatment modification, renal response should be reassessed within a further 12–24 weeks. Supportive therapy should be integrated throughout all phases of treatment and includes renin–angiotensin–aldosterone system inhibitors in patients with proteinuria or hypertension, low-sodium diet, sodium–glucose cotransporter-2 inhibitors in selected patients, lifestyle measures (including smoking cessation, diet, exercise and weight control), vaccination and management of comorbidities. RTX, rituximab.
Supportive therapy remains a key component of management. A low-sodium diet and renin–angiotensin–aldosterone system inhibitors should be used in the presence of proteinuria or hypertension and continued when proteinuria persists, given their kidney-protective effects71,72. Sodium–glucose cotransporter-2 inhibitors should be considered in patients whose disease is stable with persistent proteinuria and/or eGFR of <60 ml/min per 1.73 m2, to reduce the risk of chronic kidney disease progression and cardiovascular events73.
Subsequent long-term therapy is required to consolidate renal response and prevent relapse. This treatment regimen typically includes continued MPAA therapy, with gradual dose reduction in patients with a sustained response to treatment. Concomitantly, low-dose oral glucocorticoids can also be used but should be tapered as early as feasible to minimize cumulative exposure. The use of belimumab or obinutuzumab in combination with antimalarials and MPAAs, with or without low-dose oral glucocorticoids, is intended to maintain renal response and reduce the risk of relapse54,70. CNIs, such as voclosporin or tacrolimus, can also be used in selected patients56,68; however, prolonged use should be individualized and carefully balanced against potential safety concerns, pill burden and monitoring requirements. If renal response occurs after an initial CNIs-based regimen, transition to an MPAAs-based subsequent regimen with or without belimumab or obinutuzumab, according to relapse risk, disease phenotype, access and safety considerations, should be considered.
If the renal target, defined as complete or partial renal response, is not achieved within the expected time frame, treatment should be reassessed, including evaluation of treatment adherence, dosing and differentiation of persistent inflammatory activity from chronic damage and non-immunological causes of residual proteinuria. In patients with ongoing active lupus nephritis, optimization of conventional immunosuppressive therapies, addition of another agent or switching to an alternative treatment regimen should be considered, while avoiding prolonged glucocorticoid exposure. In patients initially treated with combination therapy, switching to another combination regimen, preferably with a different mechanism of action, should be considered. After transition to subsequent therapy or treatment modification, renal response should be reassessed within a further 12–24 weeks. When feasible, repeat kidney biopsy might be considered if the distinction between persistent inflammatory activity and chronic damage remains uncertain.
Once renal response has been achieved, subsequent conventional immunosuppressive therapy for lupus nephritis, whether maintained as monotherapy or as part of a combination regimen, should generally be continued for a total duration of at least 3 years, with treatment commonly extended to 5 years according to the clinical context. Although clinical trials assessing the efficacy and safety of these regimens have typically lasted 2 to 2.5 years49,52, the lupus nephritis expert panel recommends a longer duration to reduce the risk of renal relapse associated with premature withdrawal.
Although MPAAs have demonstrated greater efficacy than azathioprine for sustained remission in lupus nephritis, azathioprine can still be used in Latin America, particularly when access to MPAAs is limited, MPAA is not tolerated or during pregnancy and/or lactation74,75.
Across all phases of treatment, regular monitoring of renal response (including proteinuria, serum creatinine or eGFR and urinary sediment), adverse events, adherence and treatment tolerability is essential, with early reassessment and treatment adjustment when response is suboptimal.
Equity and feasibility remain central considerations in Latin America; when recommended therapies are unavailable or unaffordable, clinicians should optimize available conventional immunosuppressive regimens and adapt management strategies to local realities while maintaining alignment with evidence-based principles. Figure 3 provides the management algorithm for proliferative lupus nephritis.
Recommendation 7
For adult patients with lupus-related acute pericarditis, the panel conditionally recommends antimalarials with or without glucocorticoids in combination with colchicine over antimalarials with or without glucocorticoids in combination with NSAIDs, belimumab or anifrolumab (unchanged recommendation; conditional recommendation based on low certainty of the evidence).
Summary of rationale
No new high-quality evidence was identified to support a modification of the previous recommendation. Available data suggest that the addition of colchicine to antimalarials with or without glucocorticoids is associated with clinically meaningful benefits compared with antimalarials with or without glucocorticoids alone, particularly in reducing recurrence and improving symptom control. However, no RCTs have specifically evaluated belimumab or anifrolumab for SLE-related acute pericarditis. Accordingly, this recommendation remains consistent with the 2018 GLADEL–PANLAR guidelines14.
Considerations for implementation
Colchicine added to antimalarials with or without glucocorticoids should be considered the preferred initial therapy for acute SLE-related pericarditis, given its established role in reducing recurrences and improving symptom control76. Early initiation of colchicine is recommended to optimize clinical response and prevent relapsing disease, consistent with a T2T approach focused on rapid control of serosal inflammation.
Although no formal vote was conducted for pleuritis, a similar therapeutic approach might be considered for pleural involvement, given the shared underlying inflammatory and pathophysiological mechanisms. This extrapolation should not be interpreted as a separate formal recommendation.
NSAIDs can be added for symptomatic relief when not contraindicated. Oral glucocorticoids can be used when clinically indicated, particularly for patients with more severe symptoms or disease that has not responded adequately to initial therapy; however, they should be used at the lowest effective dose and for the shortest possible duration, with tapering as early as feasible to minimize cumulative exposure77,78. The use of biologic therapies is generally not recommended specifically for isolated acute pericarditis, given the lack of direct evidence supporting their efficacy in this setting. However, in patients with recurrent or persistent disease, inability to taper glucocorticoids to the lowest effective dose or concomitant moderate-to-severe systemic SLE activity, escalation to conventional immunosuppressive agents and/or biologic therapies, including belimumab or anifrolumab, might be considered, despite limited pericarditis-specific evidence.
Therapeutic decisions should be individualized and incorporate shared decision making, considering disease severity, recurrence risk, comorbidities and local feasibility, including access and cost considerations. In selected refractory cases, IL-1 inhibitors might also be considered79,80.
Recommendation 8
For adult patients with lupus-related diffuse alveolar haemorrhage, the panel strongly recommends treatment with intravenous glucocorticoids in combination with one or more of the following therapies: cyclophosphamide, intravenous immunoglobulin, therapeutic plasma exchange and/or rituximab over glucocorticoids alone (unchanged recommendation; strong recommendation; very low certainty of the evidence, as possible benefits exist in a life-threatening situation).
Summary of rationale
No new high-quality evidence was identified to justify modifying the previous recommendation. Given the persistently high mortality associated with diffuse alveolar haemorrhage (DAH), and the absence of comparative data between available interventions, the panel maintained the prior approach emphasizing prompt and aggressive management. Accordingly, this recommendation remains consistent with the 2018 GLADEL–PANLAR guidelines14.
Considerations for implementation
Treatment should be initiated immediately in a high-acuity setting with multidisciplinary involvement, including rheumatology, pulmonology and critical care. DAH represents a life-threatening manifestation of SLE requiring rapid recognition and prompt therapeutic intervention14.
Concurrent infection should be actively excluded or treated without delaying conventional immunosuppressive therapy when clinical suspicion of DAH is high. Supportive care should be optimized, including oxygen supplementation, ventilatory support and blood transfusion when indicated. Close monitoring for complications, including respiratory failure and secondary infections, is essential.
The combination of high-dose intravenous glucocorticoid pulses with cyclophosphamide often represents a feasible and widely available first-line strategy for the treatment of DAH in many Latin American settings, particularly when access or cost limits the use of alternative therapies. Given that DAH is a severe and life-threatening manifestation of SLE, a high-dose, intensive cyclophosphamide regimen, such as the NIH protocol, may be considered according to clinical severity and patient characteristics. However, comparative evidence establishing its superiority over the low-dose Euro-Lupus protocol regime specifically for DAH is lacking.
Intravenous immunoglobulin (IVIG), therapeutic plasma exchange and rituximab can be considered as treatment options in combination with intravenous glucocorticoids, either at presentation or following an inadequate response to initial therapy. These decisions should be guided by the balance of potential benefits against infection risk, resource availability and local feasibility.
Therapeutic decisions should be individualized and guided by disease severity, rate of progression, comorbidities and institutional capacity, recognizing the need for early escalation in cases with poor prognostic features.
Recommendation 9
For adult patients with lupus-related severe, acute neuropsychiatric manifestations of inflammatory origin, the panel conditionally recommends treatment with glucocorticoids plus cyclophosphamide over glucocorticoids alone or glucocorticoids plus rituximab (unchanged recommendation; conditional recommendation; low certainty of the evidence).
Summary of rationale
No new high-quality evidence was identified to support a modification of the previous recommendation. In the absence of comparative data between available interventions and given the potential severity of neuropsychiatric involvement in SLE, the panel maintained the prior approach favouring early and intensive conventional immunosuppressive therapy. Accordingly, this recommendation remains consistent with the 2018 GLADEL–PANLAR guidelines14.
Considerations for implementation
Management of severe, acute neuropsychiatric manifestations of inflammatory origin attributed to SLE requires a multidisciplinary approach involving rheumatologists, neurologists and psychiatrists. Accurate attribution is critical, and clinicians should make every effort to confirm that manifestations are immune-mediated and directly related to SLE, while excluding alternative causes such as infection, metabolic disturbances, drug toxicity, primary psychiatric disorders or thrombotic mechanisms, as treatment strategies differ substantially.
Once inflammatory neuropsychiatric SLE is considered likely, prompt initiation of conventional immunosuppressive therapy is recommended to prevent irreversible neurological damage. Treatment with intravenous glucocorticoid pulses followed by high-dose oral glucocorticoids in combination with cyclophosphamide is preferred; on the basis of available evidence and clinical experience, the NIH regimen is generally preferred81. In this context, the use of high-dose intravenous glucocorticoid pulses followed by oral therapy is justified to achieve rapid control of central nervous system inflammation.
Although maintenance strategies have not been formally evaluated in neuropsychiatric SLE, the use of MPAAs or azathioprine for at least 2 years should be considered, extrapolating from other severe organ manifestations82,83. Concomitant symptomatic therapy should be provided when indicated and tailored to the specific clinical presentation, including anti-seizure medications for seizures attributed to active SLE and antipsychotics for lupus-related psychosis. These treatments should be considered complementary to, but not a substitute for, conventional immunosuppressive therapy. Rituximab might be considered for refractory disease or when cyclophosphamide is contraindicated, although the optimal duration of therapy remains uncertain. Therapeutic decisions should be individualized and guided by clinical severity, rate of progression, comorbidities and local feasibility.
Recommendation 10
For adult patients with severe acute lupus-related haemolytic anaemia (haemoglobin ≤ 8 g/dl), the panel recommends treatment with high-dose glucocorticoids (unchanged recommendation; conditional recommendation; low certainty of the evidence).
Recommendation 11
For adult patients with lupus-related life-threatening haemolytic anaemia or inadequate response to glucocorticoids, the panel conditionally recommends rituximab (unchanged recommendation; conditional recommendation; low certainty of the evidence).
Summary of rationale
No new high-quality evidence was identified to support a modification of the previous recommendations. Given the potential severity of autoimmune haemolytic anaemia in SLE and the lack of comparative data, the panel maintained the prior therapeutic approach, acknowledging that cost and availability might influence treatment selection. Accordingly, these recommendations remain consistent with the 2018 GLADEL–PANLAR guidelines14.
Considerations for implementation
High-dose glucocorticoids should be administered as intravenous pulses, followed by oral therapy, with early tapering once clinical stabilization is achieved. Higher pulse doses should be reserved for life-threatening presentations. To avoid prolonged glucocorticoid exposure, early introduction of a conventional immunosuppressive therapy as a glucocorticoid-sparing strategy should be considered, particularly in the context of a high risk of relapse or those who have difficulty tapering glucocorticoids. In patients with life-threatening haemolytic anaemia, inadequate response to glucocorticoids or early relapse, rituximab should be considered, balancing potential benefits against infection risk, access and feasibility46,84,85,86.
For persistent or refractory haemolytic anaemia, cyclophosphamide and/or IVIG can be considered as rescue options when rituximab is not feasible or has failed, acknowledging the low certainty of comparative evidence. Once the acute episode is controlled, maintenance therapy with a conventional immunosuppressive therapy, preferably MPAAs, could be considered to reduce relapse risk and facilitate glucocorticoid minimization.
Recommendation 12
For adult patients with severe lupus-related thrombocytopenia (platelet count of ≤ 30 × 109/l), the panel recommends treatment with high-dose glucocorticoids (unchanged recommendation; conditional recommendation; moderate certainty of the evidence).
Recommendation 13
For adult patients with life-threatening bleeding, those requiring urgent surgery, those with concomitant infection or those with inadequate response to glucocorticoids, the panel strongly recommends IVIG with or without glucocorticoids, or rituximab in combination with glucocorticoids (unchanged recommendation; strong recommendation; moderate certainty of the evidence).
Summary of rationale
No new high-quality evidence was identified to support a modification of the previous recommendations. Accordingly, these recommendations remain consistent with the 2018 GLADEL–PANLAR guidelines14.
Considerations for implementation
Initial management should include high-dose systemic glucocorticoids, together with prompt assessment of bleeding severity, need for urgent procedures or surgery and exclusion of alternative causes of thrombocytopenia (such as drug-induced thrombocytopenia, thrombotic microangiopathy, infection, disseminated intravascular coagulation or bone-marrow disorders).
In cases of inadequate response, early relapse or when a rapid platelet increase is required (for example, life-threatening bleeding or urgent surgery) or when infection limits further immunosuppression, IVIG with or without glucocorticoids, or rituximab in combination with glucocorticoids, should be considered. In settings where rituximab is unavailable or not feasible, conventional immunosuppressive therapy can be considered.
Thrombopoietin receptor agonists (such as romiplostim or eltrombopag) might be considered in selected patients with refractory disease to increase platelet production, after careful assessment of thrombotic risk, including antiphospholipid antibody status and a history of antiphospholipid syndrome (APS).
Considerations for paediatric patients
Paediatric-specific evidence was limited across the prioritized questions, and no separate paediatric systematic review or GRADE evidence-to-decision process was conducted. Consequently, these recommendations are based predominantly on evidence from adult populations. In clinical practice, paediatric rheumatologists frequently extrapolate evidence and recommendations derived from adults; however, their application should consider the indirectness of much of the evidence, age-specific safety concerns, developmental and reproductive considerations, regulatory approvals and individual patient characteristics. Practical dosing and implementation considerations for selected interventions are summarized in Table 2.
Discussion
This document represents an update of the recommendations for the management of SLE previously published in 2018 by GLADEL and PANLAR14,15. Although maintaining the core principles of the prior version, the present document incorporates emerging evidence and evolving therapeutic strategies. A major change compared with the previous version is the earlier administration of biologic therapies for moderate-to-severe musculoskeletal and cutaneous manifestations and the use of combination treatment strategies for proliferative lupus nephritis. This strategy reflects an evolving paradigm in SLE management, characterized by earlier use of biologic therapies when appropriate, improved stratification according to disease severity and organ involvement and a stronger emphasis on T2T strategies aimed at achieving remission or, when remission is not achievable, low disease activity. Sustained remission remains the optimal long-term goal. Early intervention during a potential window of opportunity might influence disease trajectory and long-term damage accrual.
In this context, a key conceptual advance in this update is the emphasis on stratifying patients according to the severity of organ involvement and adjusting treatment intensity accordingly. The panel therefore supports earlier therapeutic optimization and the use of combination therapy in selected patients.
Conventional immunosuppressive therapies remain central to SLE management, particularly in Latin America, where access to biologic drugs and targeted therapies can be limited. Nevertheless, accumulating evidence suggests that earlier therapeutic optimization, including combination strategies in selected patients, might improve control of organ involvement, facilitate achievement of remission or low disease activity and reduce glucocorticoid exposure. Potential benefits in limiting long-term irreversible damage and modifying the disease trajectory are increasingly recognized, although the strength of the supporting evidence varies across therapies and further long-term evaluation is needed87,88. Treatment selection should therefore be individualized according to organ involvement, disease activity and severity, expected benefits and harms, previous response to treatment and feasibility.
Minimization of glucocorticoid burden represents a central therapeutic goal reinforced in this update. Chronic glucocorticoid use has consistently been identified as a major contributor to morbidity and irreversible damage in patients with SLE. In Latin America, glucocorticoid exposure has historically been higher than in other regions, partly owing to greater disease severity, lower cost and limited access to alternative therapies, as previously documented in the GLADEL cohort1. These guidelines therefore emphasize using glucocorticoids at the lowest effective dose for the shortest possible duration, with timely tapering and discontinuation whenever feasible. Achieving this goal requires early optimization of background therapy, including conventional immunosuppressive and/or biologic agents according to disease severity and organ involvement. Glucocorticoid management is addressed through a Good Practice statement 9 rather than a dedicated PICO question. Specific dosing, tapering and withdrawal strategies should therefore be individualized by the treating physician according to the clinical manifestations, disease severity, response to treatment, comorbidities and access to glucocorticoid-sparing therapies. A dedicated systematic evaluation of these strategies was not prioritized for this update.
Concurrently, important limitations in access to newer therapies persist across many countries in Latin America, owing to economic, administrative and health-system barriers. In such settings, treatment strategies based on conventional immunosuppressive regimens might remain necessary. However, acknowledging these constraints should not lead to redefinition of the therapeutic goals but rather reinforce the need to improve access to effective therapies. Ensuring equitable access to specialized care and effective treatments should therefore be considered a priority for health systems, with the potential to prevent disease-related damage, optimize the use of health care resources and improve clinical outcomes. Physicians caring for patients with SLE also have a role in advocating for equitable access and promoting health care aligned with the best available evidence. Importantly, these challenges are not unique to Latin America but are shared by regions with similar structural constraints. Accordingly, these recommendations might also provide a framework for comparable health care settings, provided that implementation is adapted to local resources and patient needs. In this context, the ACR, EULAR, Asia Pacific League of Associations for Rheumatology (APLAR) and GLADEL–PANLAR guidelines14,15,16,89,90,91 should be viewed as complementary rather than competing efforts. They draw on a shared evidence base while adapting recommendations to different health care systems, resource settings and implementation challenges. The added value of the present guidance lies in its explicit consideration of feasibility, equity, access and clinical practice in Latin America.
Several limitations of these recommendations should be acknowledged. First, although the original recommendations were supported by evidence from both RCTs and observational studies, the systematic review for this update focused on RCTs published since 2016, with searches updated through 28 February 2025. Consequently, for some clinical questions, no new evidence from RCTs was identified to meaningfully inform an update, and relevant evidence from observational studies published since 2016 might not have been captured. In these cases, the organ-specific expert group reassessed the original recommendations, including their underlying rationale and supporting evidence, and determined whether they remained sufficiently well grounded to be retained. Second, little paediatric-specific evidence was identified across the prioritized questions. Consequently, the applicability of these recommendations to children and adolescents relies largely on cautious extrapolation of evidence from studies in adults. Third, some aspects identified as highly relevant by patients, such as psychosocial support, lifestyle interventions and rehabilitation, were not included in the predefined PICO questions and therefore were not addressed through formal recommendations. Future updates should be aimed at integrating these domains to provide a more comprehensive and patient-centred framework. Fourth, a separate PICO question evaluating prespecified glucocorticoid tapering and withdrawal schedules was not prioritized for this update and will be considered for prioritization in future updates. For the present guideline, the panel adopted a target-based rather than schedule-based approach, addressed through Good Practice statement 9, with practical dosing guidance provided in Table 2. Fifth, the APS-related recommendations from the 2018 guidelines were not updated, and newer evidence on direct oral anticoagulants was not systematically reviewed. Nevertheless, current international guidance supports the continued use of vitamin K antagonists for thrombotic APS and combination therapy with low-dose aspirin and heparin in obstetric APS, and the original recommendations remain applicable92,93. As the field continues to evolve, addressing current gaps in evidence will be a priority for GLADEL and PANLAR in future updates, with the aim of providing a more comprehensive and clinically relevant framework for APS management within SLE. Finally, the phase III ALLEGORY trial evaluating obinutuzumab in patients with active SLE without active proliferative or membranous lupus nephritis was published after completion of the systematic review and therefore could not be incorporated into the current recommendations94. Its findings might influence future recommendations for moderate-to-severe non-renal SLE by informing whether obinutuzumab should be considered as an additional therapeutic option. This evidence will be formally evaluated through a planned ‘living guideline’ process, which is discussed in more detail later in this section95.
These updated guidelines have several important strengths. They were developed using a rigorous and transparent methodology based on the GRADE framework, incorporating systematic evidence reviews of RCTs and, when appropriate, network meta-analyses to compare available interventions. In addition, clinical effects thresholds were considered for each intervention to better inform the interpretation of clinical benefits and support decision making. Patients actively participated in multiple stages of the development process, guaranteeing that their perspectives shaped the recommendations. Finally, these recommendations were formulated through structured consensus among a multidisciplinary panel of experts from across Latin America and explicitly incorporate regional considerations such as disease severity, health-system variability, feasibility and access to therapies, ensuring that the guidance is both evidence based and contextually relevant.
The therapeutic landscape of SLE continues to evolve rapidly. Emerging approaches, including chimeric antigen receptor (CAR) T cell therapies, bi-specific and tri-specific antibodies that target B cells and T cells and novel small molecules directed against intracellular signalling pathways, have shown encouraging preliminary results in early clinical studies and are currently being evaluated in ongoing clinical trials. Although these therapies were outside the scope of the predefined PICO questions underpinning the present guideline, and the available evidence was insufficient to support evidence-based GRADE recommendations, they have the potential to influence future treatment algorithms. As additional evidence becomes available, these therapies are likely to be considered in future guideline updates95.
The present document was not developed as a living guideline; however, to ensure that future recommendations remain clinically useful and up to date, GLADEL and PANLAR plan to adopt a living-guidelines approach for future updates95. This approach will include ongoing surveillance of new evidence, particularly RCTs and high-quality extension studies, continuous updating of ‘living’ systematic reviews and periodic reassessment by a standing expert panel. When new evidence is judged to have the potential to change the balance of benefits and harms, certainty of evidence, feasibility, access or clinical applicability of a particular treatment in Latin America, the corresponding recommendation will be reviewed and updated. Through this process, we aim to reduce the delay between emerging evidence and clinical guidance, while maintaining a transparent, evidence-based and regionally applicable recommendation process.
Conclusions
This update of the GLADEL–PANLAR guidelines reflects important advances in the management of SLE, incorporating emerging evidence and evolving therapeutic strategies, particularly in musculoskeletal, cutaneous and kidney disease. These recommendations promote a more proactive and individualized approach based on organ involvement and disease severity, including earlier therapeutic optimization, the selective use of combination therapies and strategies aimed at minimizing glucocorticoid exposure. Although important challenges in access to newer therapies persist in Latin America, these guidelines provide a practical, evidence-based and context-adapted framework for improving disease control, reducing long-term damage and enhancing patient outcomes. Importantly, core therapeutic principles are aligned with major international guidelines, including EULAR, KDIGO, ACR and APLAR16,17,89,90,91, while incorporating regional adaptations that enhance their relevance in real-world settings. These recommendations support a shift towards earlier, more precise and goal-directed management of SLE, with the aim of improving long-term outcomes; however, achieving these improvements will depend not only on advances in therapeutic strategies but also on ensuring equitable access to specialized care and effective treatments across diverse health care systems.
References
Pons-Estel, B. A. et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics”. Medicine 83, 1–17 (2004).
Alarcon, G. S. et al. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum. 44, 2797–2806 (2001).
Alarcon, G. S. et al. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum. 45, 191–202 (2001).
Alarcon-Segovia, D. et al. Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum. 52, 1138–1147 (2005).
Pons-Estel, G. J., Alarcon, G. S., Scofield, L., Reinlib, L. & Cooper, G. S. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin. Arthritis Rheum. 39, 257–268 (2010).
Sanchez, E. et al. Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian-European populations. Arthritis Rheum. 64, 3687–3694 (2012).
Alarcon-Riquelme, M. E. et al. Genome-wide association study in an Amerindian ancestry population reveals novel systemic lupus erythematosus risk loci and the role of European admixture. Arthritis Rheumatol. 68, 932–943 (2016).
Guarnizo-Zuccardi, P. et al. Cytokine gene polymorphisms in Colombian patients with systemic lupus erythematosus. Tissue Antigens 70, 376–382 (2007).
Duran, S., Apte, M. & Alarcon, G. S.LUMINA study group poverty, not ethnicity, accounts for the differential mortality rates among lupus patients of various ethnic groups. J. Natl Med. Assoc. 99, 1196–1198 (2007).
Ugarte-Gil, M. F. et al. Disease features and outcomes in United States lupus patients of Hispanic origin and their Mestizo counterparts in Latin America: a commentary. Rheumatology 55, 436–440 (2016).
Pons-Estel, G. J. et al. The impact of rural residency on the expression and outcome of systemic lupus erythematosus: data from a multiethnic Latin American cohort. Lupus 21, 1397–1404 (2012).
Yazdany, J. et al. Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States. Arthritis Care Res. 66, 617–624 (2014).
Contreras, G. et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int. 69, 1846–1851 (2006).
Pons-Estel, B. A. et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR). Ann. Rheum. Dis. 77, 1549–1557 (2018).
Cardiel, M. H. et al. Therapeutic guidelines for Latin American lupus patients: methodology. J. Clin. Rheumatol. 24, 41–44 (2018).
Fanouriakis, A. et al. EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. Ann. Rheum. Dis. 85, 75–90 (2026).
Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int. 105, S1–S69 (2024).
Schunemann, H. J. et al. The development methods of official GRADE articles and requirements for claiming the use of GRADE — a statement by the GRADE guidance group. J. Clin. Epidemiol. 159, 79–84 (2023).
Izcovich, A. et al. Systematic review and network meta-analysis of initial treatments for lupus nephritis. Kidney Int. Rep. 10, 2977–2990 (2025).
GLADEL-PANLAR Clinical Practice Guidelines for the Management of Systemic Lupus Erythematosus: 2025 Update https://ies.epistemonikos.org/synthesis/review/66cde5fdda97830560d8d6ad?tab=active:_new_drugs (Epistemonikos Foundation, accessed 25 October 2026).
Graham, R., Mancher, M., Miller Wolman, D. et al. (eds). Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines Clinical Practice Guidelines We Can Trust. (National Academies Press, 2011).
Chen, Y. et al. A reporting tool for practice guidelines in health care: the RIGHT statement. Ann. Intern. Med. 166, 128–132 (2017).
Morgano, G. P. et al. Defining decision thresholds for judgments on health benefits and harms using the grading of recommendations assessment, development, and evaluation (GRADE) evidence to decision (EtD) frameworks: a randomized methodological study (GRADE-THRESHOLD). J. Clin. Epidemiol. 179, 111639 (2025).
Dewidar, O. et al. GRADE guidance: update on developing good practice statements in guidelines. Ann. Intern. Med. 179, 430–439 (2026).
Urowitz, M. B. et al. The bimodal mortality pattern of systemic lupus erythematosus. Am. J. Med. 60, 221–225 (1976).
Doria, A., Gatto, M., Zen, M., Iaccarino, L. & Punzi, L. Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmun. Rev. 13, 770–777 (2014).
Bruce, I. N. et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus international collaborating clinics (SLICC) Inception Cohort. Ann. Rheum. Dis. 74, 1706–1713 (2015).
Aringer, M. et al. European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 71, 1400–1412 (2019).
van Vollenhoven, R. F. et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann. Rheum. Dis. 73, 958–967 (2014).
van Vollenhoven, R. F. et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci. Med. 8, e000538 (2021).
Franklyn, K. et al. Definition and initial validation of a lupus low disease activity state (LLDAS). Ann. Rheum. Dis. 75, 1615–1621 (2016).
Gladman, D. D., Ibañez, D. & Urowitz, M. B. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 29, 288–291 (2002).
Gladman, D. et al. The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 39, 363–369 (1996).
Piga, M. et al. Physician global assessment international standardisation COnsensus in systemic lupus erythematosus: the PISCOS study. Lancet Rheumatol. 4, e441–e449 (2022).
Bass, A. R. et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Care Res. 75, 449–464 (2023).
Furer, V. et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann. Rheum. Dis. 79, 39–52 (2020).
Pileggi, G. C. S. et al. Brazilian Society of Rheumatology — 2025 recommendations on vaccination in immune-mediated rheumatic diseases. Adv. Rheumatol. 66, 14 (2026).
Cosentino, V., Larroude, M. S. & Schneeberger, E. Grupo de expertos de la Sociedad Argentina De Infectología (SADI) & Nacinovich, F. Consenso de recomendaciones de vacunas en adultos con enfermedades reumáticas inflamatorias crónicas autoinmunes. Rev. Argent. Reumatol. 33, 1–24 (2022).
Parisis, D., Bernier, C., Chasset, F. & Arnaud, L. Impact of tobacco smoking upon disease risk, activity and therapeutic response in systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun. Rev. 18, 102393 (2019).
Marmor, M. F. et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology 123, 1386–1394 (2016).
Yusuf, I. H., Foot, B. & Lotery, A. J. The Royal College of Ophthalmologists recommendations on monitoring for hydroxychloroquine and chloroquine users in the United Kingdom (2020 revision): executive summary. Eye 35, 1532–1537 (2021).
Finbloom, D. S., Silver, K., Newsome, D. A. & Gunkel, R. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J. Rheumatol. 12, 692–694 (1985).
Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721–731 (2011).
Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382, 211–221 (2020).
Albrecht, J. et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J. Invest. Dermatol. 125, 889–894 (2005).
Fanouriakis, A. et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann. Rheum. Dis. 83, 15–29 (2024).
Sheikh, S. Z. et al. Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial. Lancet Rheumatol. 3, e122–e130 (2021).
Wallace, D. J. et al. Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data. Lupus 31, 1649–1659 (2022).
Bruce, I. N. et al. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Rheumatol. 3, e101–e110 (2021).
Manzi, S. et al. Efficacy and safety of subcutaneous anifrolumab in systemic lupus erythematosus: a randomized, phase 3 study. Arthritis Rheumatol. 78, 1258–1267 (2026).
Tummala, R. et al. Safety profile of anifrolumab in patients with active systemic lupus erythematosus: an integrated analysis of phase II and III trials. Lupus Sci. Med. 8, e000464 (2021).
Merrill, J. T. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222–233 (2010).
Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64, 1215–1226 (2012).
Furie, R. et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N. Engl. J. Med. 383, 1117–1128 (2020).
Furie, R. et al. Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study. Clin. J. Am. Soc. Nephrol. 17, 1620–1630 (2022).
Zhang, H. et al. Multitarget therapy for maintenance treatment of lupus nephritis. J. Am. Soc. Nephrol. 28, 3671–3678 (2017).
Furie, R. A. et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N. Engl. J. Med. 392, 1471–1483 (2025).
Saxena, A. et al. Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial. Arthritis Rheumatol. 76, 59–67 (2024).
Appel, G. B. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20, 1103–1112 (2009).
Isenberg, D. et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology 49, 128–140 (2010).
Houssiau, F. A. et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 50, 3934–3940 (2004).
Houssiau, F. A. et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 46, 2121–2131 (2002).
Austin, H. A. III et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N. Engl. J. Med. 314, 614–619 (1986).
Boumpas, D. T. et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340, 741–745 (1992).
Illei, G. G. et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann. Intern. Med. 135, 248–257 (2001).
Brunner, H. I. et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann. Rheum. Dis. 79, 1340–1348 (2020).
Brunner, H. I. et al. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open. 7, e001747 (2021).
Rovin, B. H. et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397, 2070–2080 (2021).
Liu, Z. et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann. Intern. Med. 162, 18–26 (2015).
Furie, R. A. et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 81, 100–107 (2022).
Ku, E. et al. Angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers for advanced chronic kidney disease : a systematic review and retrospective individual participant-level meta-analysis of clinical trials. Ann. Intern. Med. 177, 953–963 (2024).
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 100, S1–S276 (2021).
Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436–1446 (2020).
Houssiau, F. A. et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial. Ann. Rheum. Dis. 69, 2083–2089 (2010).
Dooley, M. A. et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N. Engl. J. Med. 365, 1886–1895 (2011).
Imazio, M. et al. A randomized trial of colchicine for acute pericarditis. N. Engl. J. Med. 369, 1522–1528 (2013).
Adler, Y. et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 36, 2921–2964 (2015).
Imazio, M., Gaita, F. & LeWinter, M. Evaluation and treatment of pericarditis: a systematic review. JAMA 314, 1498–1506 (2015).
Klein, A. L. et al. Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis. N. Engl. J. Med. 384, 31–41 (2021).
Schulz-Menger, J. et al. The 2025 European Society of Cardiology guidelines for myocarditis and pericarditis and the evolving role of cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 28, 102674 (2026).
Barile-Fabris, L. et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann. Rheum. Dis. 64, 620–625 (2005).
Trevisani, V. F., Castro, A. A., Neves Neto, J. F. & Atallah, A. N. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst. Rev. 2, CD002265 (2006).
Papachristos, D. A., Oon, S., Hanly, J. G. & Nikpour, M. Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: a systematic review. Semin. Arthritis Rheum. 51, 49–71 (2021).
Barcellini, W., Fattizzo, B. & Zaninoni, A. Current and emerging treatment options for autoimmune hemolytic anemia. Expert. Rev. Clin. Immunol. 14, 857–872 (2018).
Barcellini, W. & Fattizzo, B. Management of autoimmune hemolytic anemia. Hematol. Am. Soc. Hematol. Educ. Program 2025, 305–311 (2025).
D’Arena, G. et al. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. Eur. J. Haematol. 79, 53–58 (2007).
Askanase, A. D. et al. Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations. Lupus Sci. Med. 11, e001124 (2024).
Askanase, A. D. et al. Disease-modifying therapies in lupus nephritis: a narrative review evaluating currently used pharmacologic agents. Rheumatol. Ther. 12, 421–434 (2025).
Sammaritano, L. R. et al. 2025 American College of Rheumatology (ACR) guideline for the treatment of systemic lupus erythematosus. Arthritis Care Res. 78, 815–839 (2026).
Sammaritano, L. R. et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Rheumatol. 77, 1115–1135 (2025).
Mok, C. C. et al. The 2024 APLAR consensus on the management of lupus nephritis. Int. J. Rheum. Dis. 28, e70021 (2025).
Tektonidou, M. G. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann. Rheum. Dis. 78, 1296–1304 (2019).
Pengo, V. et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132, 1365–1371 (2018).
Furie, R. A. et al. Efficacy and safety of obinutuzumab in active systemic lupus erythematosus. N. Engl. J. Med. 395, 243–254 (2026).
Arnaud, L. & Pons-Estel, G. J. Towards a global collaborative approach to living guideline development in rheumatology. Nat. Rev. Rheumatol. 22, 667–668 (2026).
Acknowledgements
The authors are deeply grateful to all the patients who contributed to the development of these guidelines, whose perspectives helped to inform the identification of key clinical priorities. We thank A. Duarte García for his valuable contributions and suggestions as an external reviewer for the guidelines. We also acknowledge the contributions of all investigators, collaborators and participating centres within the GLADEL network, and the methodological support teams involved in the evidence synthesis and guideline development process.
Author information
Authors and Affiliations
Centro Regional de Enfermedades Autoinmunes y Reumáticas, Grupo Oroño (GO-CREAR), Rosario, Argentina
Guillermo J. Pons-Estel, Romina E. Nieto, Rosana Quintana, Rosa Serrano & Bernardo A. Pons-Estel
Centro Traumatológico Bariloche, Bariloche, Río Negro, Argentina
Carolina A. Isnardi
Servicio de Clínica Médica, Hospital Alemán, Universidad del Salvador, Facultad de Medicina, Buenos Aires, Argentina
Ariel Izcovich
Universidad Nacional de Asunción, Facultad de Ciencias Médicas, San Lorenzo, Paraguay
Isabel Acosta Colman & Jhonatan Losanto
Hospital Central “Dr. Ignacio Morones Prieto” y Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico
Carlos Abud-Mendoza
Hospital Alemán de Buenos Aires, Buenos Aires, Argentina
Camila Agnoletti, Agustin Bengolea & Moira M. Pissinis
Department of Medicine, Division of Clinical Immunology and Rheumatology, School of Medicine, The University of Alabama, Birmingham, AL, USA
Graciela S. Alarcón
Departamento de Medicina, Facultad de Medicina, Universidad Peruana Cayetano Heredia, Lima, Peru
Graciela S. Alarcón
Hospital Córdoba, Facultad de Ciencias Médicas Universidad Nacional de Córdoba, Córdoba, Argentina
Paula Alba
Rheumatology Department, Hospital Edgardo Rebagliati Martins, EsSalud, Lima, Peru
Gustavo R. León Amenero
Department of Orthopedics, Rheumatology and Traumatology, School of Medical Science, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil
Simone Appenzeller
Clínica de la Costa, Universidad Simón Bolívar, Facultad de Ciencias de la Salud, Barranquilla, Atlántico, Colombia
Gustavo Aroca
Servicio de Reumatología, Hospital San Martín, La Plata, Argentina
Valeria Arturi
Hospital Italiano de Córdoba, Córdoba, Argentina
Alejandra Babini & Natalia S. Morales
Hospital das Clínicas, Universidade Federal de Goiás, Goiânia, Goiás, Brazil
Vitalina de Sousa Barbosa
Hospital Angeles Pedregal, Mexico City, Mexico
Leonor Barile-Fabris
Servicio de Reumatología, Hospital Ángel C. Padilla, Tucumán, Argentina
Verónica Bellomio
Servicio de Reumatología, Hospital Escuela Eva Perón, Granadero Baigorria, Santa Fe, Argentina
Guillermo Berbotto
Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
Eloisa Bonfa & Eduardo F. Borba
Servicio de Inmunología y Reumatología, Hospital Nacional Cayetano Heredia, Universidad Peruana Cayetano Heredia, Lima, Peru
Armando Calvo
Fundación Valle del Lili, Universidad Icesi, Cali, Colombia
Carlos A. Cañas
Unidad Académica Clínica Médica, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
Alvaro Danza & Martin Rebella
Hospital de Niños Dr. Ricardo Gutiérrez, Buenos Aires, Argentina
Graciela Espada
Universidad de Buenos Aires, Buenos Aires, Argentina
Graciela Espada
Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
Jorge A. Esquivel-Valerio
Institute of Inflammatory and Immune-Mediated Diseases, Hospital Universitario Mayor Méderi, Universidad del Rosario, Bogotá, Colombia
Diana C. Fernández-Ávila
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Hilda Fragoso-Loyo
Departamento de Medicina, Universidad de Oriente, Ciudad Bolívar, Venezuela
Yurilis Fuentes-Silva
Servicio de Reumatología, HIGA San Martin, La Plata, Argentina
Mercedes García
Department of Rheumatology, Hospital Clinic, Barcelona, IDIBAPS and University of Barcelona, Barcelona, Spain
José A. Gómez-Puerta
Division of Rheumatology, Department of Internal Medicine, School of Medicine, Universidad de Antioquia, Medellín, Colombia
Luis A. González
Servicio de Reumatología, Hospital Señor del Milagro, Salta, Argentina
Vicente Juárez
Departamento de Reumatologia, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
Evandro M. Klumb
Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina
Ana Malvar & Martín Ragusa
Division of Rheumatology, Centro de Ciências Médicas, Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil
Henrique de Ataide Mariz
Facultad de Medicina, Universidad San Sebastián, Santiago, Chile
Loreto Massardo
Hospital Dr. Franco Ravera Zunino, Rancagua, Chile
Loreto Massardo
Hospital General de Agudos Doctor Ramos Mejía, Buenos Aires, Argentina
Marina Micelli
Division of Rheumatology, Department of Internal Medicine, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Odirlei A. Monticielo
Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador
Mario J. Moreno
Reumatología e Investigación Clínica, Hospital Padre Billini, Santo Domingo, Dominican Republic
Roberto Muñoz Louis
Sección de Reumatología, Hospital del Salvador, Facultad de Medicina, Universidad de Chile, Santiago de Chile, Chile
Óscar Neira
Unidad de Reumatología, Facultad de Medicina, Universidad del Desarrollo-Clínica Alemana de Santiago, Santiago de Chile, Chile
Óscar Neira
Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina
Nicolas Pérez
Rheumatology and Immunology Section, CEMIC, Buenos Aires, Argentina
Cecilia Pisoni
Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
Margarita Portela-Hernández
Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, Colombia
Gerardo Quintana-López
Hospital Universitario Fundación Santa Fe, Bogotá, Colombia
Gerardo Quintana-López
Hospital Universitario Nacional de Colombia, Bogotá, Colombia
Gerardo Quintana-López
Unidad Médica de Alta Especialidad, Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Mexico City, Mexico
Miguel Ángel Saavedra
Hospital Privado, Centro Médico de Córdoba, Córdoba, Argentina
Verónica Saurit
Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Marina Scolnik
Pediatric Rheumatology Unit, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Clovis A. Silva
Departamento de Reumatología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
Luis H. Silveira
Centro de Referencia en Osteoporosis & Reumatología, Cali, Colombia
Carlos E. Toro-Gutierrez
St. Joseph’s Hospital Hamilton Healthcare, Division of Rheumatology, McMaster University, Hamilton, Ontario, Canada
Carlos E. Toro-Gutierrez
Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil
Edgard Torres dos Reis-Neto
Laboratorio de Evaluación de Tecnologías e Investigación Sanitaria, Universidad Nacional de Rio Negro, Bariloche, Rio Negro, Argentina
Fernando Tortosa
Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru
Manuel F. Ugarte-Gil
Rheumatology Department, Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru
Manuel F. Ugarte-Gil
Department of Nephrology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Juan M. Mejia-Vilet
Servicio de Reumatología, Universidad de Antioquia, Medellín, Colombia
Gloria Vásquez
Department of Rheumatology, Hôpitaux Universitaires de Strasbourg, INSERM UMR-S 1109, Centre National de Référence des Maladies Auto-immunes Systémiques Rares, Strasbourg, France
Laurent Arnaud
University of California, San Francisco, CA, USA
Maria Dall’Era
Rheumatology Unit, Department of Medicine and Therapeutics, Korlebu Teaching Hospital, University of Ghana Medical School, Accra, Ghana
Dzifa Dey
Rheumatology and Clinical Immunology Unit, Attikon University Hospital, Medical School National Kapodistrian University of Athens, Athens, Greece
Antonios Fanouriakis
Hospital for Skin Diseases (Institute of Dermatology), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Qianjin Lu
Department of Dermatology, University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, USA
Victoria Werth
Authors
- Guillermo J. Pons-Estel
- Carolina A. Isnardi
- Romina E. Nieto
- Ariel Izcovich
- Isabel Acosta Colman
- Carlos Abud-Mendoza
- Camila Agnoletti
- Graciela S. Alarcón
- Paula Alba
- Gustavo R. León Amenero
- Simone Appenzeller
- Gustavo Aroca
- Valeria Arturi
- Alejandra Babini
- Vitalina de Sousa Barbosa
- Leonor Barile-Fabris
- Verónica Bellomio
- Agustin Bengolea
- Guillermo Berbotto
- Eloisa Bonfa
- Eduardo F. Borba
- Armando Calvo
- Carlos A. Cañas
- Alvaro Danza
- Graciela Espada
- Jorge A. Esquivel-Valerio
- Diana C. Fernández-Ávila
- Hilda Fragoso-Loyo
- Yurilis Fuentes-Silva
- Mercedes García
- José A. Gómez-Puerta
- Luis A. González
- Vicente Juárez
- Evandro M. Klumb
- Jhonatan Losanto
- Ana Malvar
- Henrique de Ataide Mariz
- Loreto Massardo
- Marina Micelli
- Odirlei A. Monticielo
- Natalia S. Morales
- Mario J. Moreno
- Roberto Muñoz Louis
- Óscar Neira
- Nicolas Pérez
- Cecilia Pisoni
- Moira M. Pissinis
- Margarita Portela-Hernández
- Gerardo Quintana-López
- Rosana Quintana
- Martín Ragusa
- Martin Rebella
- Miguel Ángel Saavedra
- Verónica Saurit
- Marina Scolnik
- Rosa Serrano
- Clovis A. Silva
- Luis H. Silveira
- Carlos E. Toro-Gutierrez
- Edgard Torres dos Reis-Neto
- Fernando Tortosa
- Manuel F. Ugarte-Gil
- Juan M. Mejia-Vilet
- Gloria Vásquez
- Laurent Arnaud
- Maria Dall’Era
- Dzifa Dey
- Antonios Fanouriakis
- Qianjin Lu
- Victoria Werth
- Bernardo A. Pons-Estel
Corresponding author
Correspondence to Guillermo J. Pons-Estel.
Ethics declarations
Competing interests
G.J.P.-E. has received grants and consulting fees and has participated as a speaker, advisor and/or steering committee member for AstraZeneca, Boehringer Ingelheim, GSK, Janssen, Novartis, Pfizer, RemeGen, Sanofi and Werfen Diagnostics. P.A. has received speaker fees from AstraZeneca and GlaxoSmithKline. S.A. has received honoraria for lectures from AstraZeneca and GSK. E.F.B. has received research educational grants from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; #303378/2022–0, awarded to E.F.B.). D.C.F.-Á. has received grants and consulting fees from AstraZeneca and Janssen and has participated as a speaker and/or advisor for these companies. H.F.-L. has received speaker fees from AstraZeneca and Roche. J.A.G.-P. has received fees for lectures from AstraZeneca, Boehringer Ingelheim, GSK and Otsuka. E.M.K. has received consultancy and/or advisory fees from AstraZeneca, Roche and AbbVie. J.L. has served as a Medical Advisor for Boller. A.M. has received speaker and/or advisory fees from AstraZeneca, BMS, GSK, Roche, Biogen, Kezar, Novartis and Pfizer. H.A.M. has served as a speaker and received payments for lectures, manuscript preparation and educational activities from GSK and AstraZeneca. M.M. has received speaker fees from GSK. O.A.M. has received consulting fees from AstraZeneca, GSK, Janssen and Roche and payments or honoraria for lectures, presentations, speakers bureau, manuscript writing or educational events from AbbVie, AstraZeneca, GSK, Janssen, UCB and Roche. M.S. has received grants and consulting fees and has participated as a speaker, advisor and/or on a steering committee for AstraZeneca, GSK and Janssen. C.A.S. has received support from Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP; #2022/12925-8) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; #304984/2020-5). C.E.T.G. has received speaker and/or advisory fees from AstraZeneca, GSK, Roche, Novartis, Johnson & Johnson, Boehringer Ingelheim and AbbVie. E.T.R.N. has received speaker fees and/or consultancy fees from AstraZeneca, GSK, Roche and Novartis and participates in clinical research with AbbVie, BMS and Novartis. M.F.U.-G. has received grant support from Janssen and speaker and/or advisory fees from AstraZeneca, Adium, GSK, Ferrer and Novartis. J.M.M.-V. has received fees for lectures from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffmann-La Roche and Novartis. L.A. has received honoraria from Alexion, Alpine, Amgen, AstraZeneca, AbbVie, Biogen, BMS, Boehringer Ingelheim, GSK, Grifols, Janssen, LFB, Lilly, Medac, Novartis, Ono Pharma, Pfizer, Roche-Chugai, Sêmeia and UCB. M.D. has served as an advisor to GSK, AstraZeneca, Biogen, Genentech, Merck-Serono and Novartis. A.F. has received advisory and honoraria fees from AstraZeneca, GSK, Lilly, BMS, Roche, UCB and Swixx Biopharma. V.W. has received grants from Biogen, Gilead, AstraZeneca, Amgen, Horizon, Ventus and Viela and has consulted for AbbVie, Almirall, Alpine Immune Sciences, Architect Therapeutics, Amgen, Anaptysbio, AstraZeneca, Biogen, BMS, Cabaletta Bio, Calyx, Caribou, Cugene, Duality Therapeutics, Eli Lilly, EMD Serono, Evommune, Exo Therapeutics, Gilead, Glycoera, GSK, Immunovant, Inmagene, Innovaderm, Janssen, Kyowa Kirin, Lilly, Merck, Nektar, Novartis, Nuvig Pharmaceuticals, Sanofi, Takeda, UCB, Ventus, Viela Bio, Xencor, Prolium, Alumis and Atticus. The University of Pennsylvania owns the copyright for CLASI and CLE-IGA. B.A.P.-E. has received speaker fees from Novartis, GSK and AstraZeneca and has served on advisory boards for GSK and AstraZeneca. All other authors declare no competing interests.
Peer review
Peer review information
Nature Reviews Rheumatology thanks Sandra Navarra, who co-reviewed with Ma. Theresa Collante; Maria Tektonidou; and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Pons-Estel, G.J., Isnardi, C.A., Nieto, R.E. et al. GLADEL–PANLAR clinical practice guidelines for the management of systemic lupus erythematosus: 2025 update. Nat Rev Rheumatol (2026). https://doi.org/10.1038/s41584-026-01450-x
Accepted: 02 October 2026
Published: 12 November 2026
Version of record: 12 November 2026
DOI: https://doi.org/10.1038/s41584-026-01450-x
来源:Nature 健康护理主题 · nature.com